Press releaseGlobe Newswire
Cartesian Therapeutics
RNAC · NASDAQ
$6.40+$0.315 (+5.18%)TodayMarket closed ·
Prev close $6.08
Latest news
- News
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
- Press releaseGlobe Newswire
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- NewsVandana Singh
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
- Press releaseGlobe Newswire
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
- Press releaseGlobe Newswire
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
- Press releaseGlobe Newswire
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- News
Insights into Cartesian Therapeutics Q4 Earnings
- Press releaseGlobe Newswire
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
- NewsVandana Singh
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment
- Press releaseGlobe Newswire
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
- NewsVandana Singh
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
- Press releaseGlobe Newswire
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
- Press releaseGlobe Newswire
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
- News
Cartesian Therapeutics Q2 EPS $0.50 Compared With $0.54 YoY, Sales Total $298.000K
- NewsVandana Singh
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
- NewsVandana Singh
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?
- NewsRishabh Mishra
US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert
- NewsVandana Singh
Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients
- NewsAvi Kapoor
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases
- Press releaseGlobe Newswire
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
- Press releaseGlobe Newswire
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
- Press releaseGlobe Newswire
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.